IMMUTEP Ltd
Immutep develops immunotherapies for cancer and autoimmune disease, focusing on LAG-3-targeted therapeutics that stimulate or suppress immune responses.
6-KNov 10Latest SEC filing
Jul 13Latest story
July 2026
Immutep develops immunotherapies for cancer and autoimmune disease, focusing on LAG-3-targeted therapeutics that stimulate or suppress immune responses.